Method for preparing freeze-dried menthol powder, freeze-dried menthol powder prepared thereby, and stick for dry powder inhaler comprising same
The method of freeze-drying menthol with beta-cyclodextrin and ethanol addresses volatility issues, ensuring high yield and ease of use in dry powder inhalers, thus stabilizing menthol in smoking products.
Patent Information
- Application Number
- PCT/KR2026/005295
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-09
- Publication Date
- 2026-11-12
AI Technical Summary
Menthol's high volatility leads to significant loss during manufacturing and distribution of smoking products, causing variations in cooling sensation and increased costs due to complex methods like encapsulation or polymer mixing.
A method involving the preparation of a menthol freeze-drying composition by mixing beta-cyclodextrin with water, menthol with ethanol, and optionally a cryoprotectant, followed by freezing and drying at low temperatures to produce freeze-dried menthol powder.
The method maintains a high yield of menthol in powder form, simplifies storage, and facilitates its use in dry powder inhalers, reducing manufacturing complexity and costs.
Smart Images

Figure KR2026005295_12112026_PF_FP_ABST
Abstract
Description
Method for manufacturing freeze-dried menthol powder, freeze-dried menthol powder manufactured thereby, and a stick for a dry powder inhaler containing the same
[0001] The embodiments relate to a method for manufacturing freeze-dried menthol powder, freeze-dried menthol powder manufactured thereby, and a stick for a dry powder inhaler containing the same. More specifically, it is intended to manufacture highly volatile menthol into freeze-dried powder.
[0002] Menthol is a representative flavoring substance added to smoking products, and it is an ingredient that changes the smoking experience by providing a unique coolness and refreshing scent.
[0003] However, menthol is highly volatile and tends to evaporate easily even at relatively low temperatures. Due to this volatility, menthol is lost during the manufacturing and distribution of smoking products, making it difficult to provide the intended cooling sensation and potentially causing variations between products depending on the storage environment.
[0004] To solve this, methods such as including menthol in capsules or mixing menthol with polymer materials to reduce volatility and control the release rate have been used, but there were problems such as high initial development costs, complex manufacturing processes, and poor versatility.
[0005] The embodiments provide a method for manufacturing freeze-dried menthol powder that can produce highly volatile menthol in powder form to solve the aforementioned problems.
[0006] In addition, the present invention provides a menthol freeze-dried powder manufactured through a method for manufacturing menthol freeze-dried powder according to the embodiments, and a stick for a dry powder inhaler containing the same.
[0007] The problems to be solved through the embodiments are not limited to those described above, and problems not mentioned will be clearly understood by those skilled in the art to which the embodiments belong from this specification and the attached drawings.
[0008] A method for manufacturing menthol freeze-dried powder according to one embodiment may comprise: a) a step of preparing a first solution by mixing beta-cyclodextrin and water; b) a step of preparing a second solution by mixing menthol and ethanol; c) a step of preparing a menthol freeze-drying composition by mixing the first solution and the second solution; d) a step of freezing the menthol freeze-drying composition at -40 ℃ to -50 ℃ using a deep freezer; and e) a step of drying the composition frozen in step d) at -40 ℃ to -50 ℃.
[0009] The menthol freeze-dried powder according to one embodiment may be manufactured through the method for manufacturing menthol freeze-dried powder described above.
[0010] A stick for a dry powder inhaler according to one embodiment may include the above-described menthol freeze-dried powder.
[0011] According to the method for manufacturing menthol freeze-dried powder according to the embodiments, highly volatile menthol can be provided in powder form. According to the embodiments, freeze-dried powder having a relatively high powder yield and menthol yield can be provided.
[0012] The menthol freeze-dried powder produced by the method for producing menthol freeze-dried powder according to the embodiments is easy to store and can be easily applied to a stick for a dry powder inhaler.
[0013] The effects of the embodiments are not limited to the effects described above, and unmentioned effects will be clearly understood by those skilled in the art from this specification and the accompanying drawings.
[0014] FIG. 1 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to one embodiment.
[0015] FIG. 2 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to another embodiment.
[0016] FIG. 3 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to another embodiment.
[0017] The terms used in the embodiments have been selected based on currently widely used general terms whenever possible, taking into account their functions; however, these may vary depending on the intent of those skilled in the art, case law, or the emergence of new technologies. Additionally, in specific cases, the applicant has arbitrarily selected terms, and in such instances, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in the embodiments must be defined not merely by their names, but based on their meanings and the overall context of the embodiments.
[0018] When a part of a specification is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. Furthermore, terms such as "-part" or "-module" as used in the specification refer to a unit that processes at least one function or operation, and this may be implemented in hardware or software, or as a combination of hardware and software.
[0019] As used herein, when an expression such as "at least one" precedes an arranged component, it modifies the entire set of components rather than each individual component. For example, the expression "at least one of a, b, and c" should be interpreted as including a, b, and c, or a and b, a and c, b and c, or a, b, and c.
[0020] Embodiments of the present invention are described below with reference to the attached drawings so that those skilled in the art can easily implement them. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein.
[0021] Throughout the specification, embodiments are any classifications intended to facilitate the description of the invention, and each embodiment is not required to be mutually exclusive. For example, configurations disclosed in one embodiment may be applied and / or implemented in other embodiments and may be applied and / or implemented with modifications to the extent that they do not depart from the scope of the disclosure.
[0022] Furthermore, the terms used in this disclosure are for describing the embodiments and are not intended to limit the embodiments. In this disclosure, the singular form includes the plural form unless specifically stated otherwise.
[0023] Below, a method for manufacturing menthol freeze-dried powder according to embodiments is described in detail with reference to the attached drawings. However, it is not limited to the embodiments described herein.
[0024] FIG. 1 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to one embodiment.
[0025] Referring to FIG. 1, a method for manufacturing menthol freeze-dried powder according to an embodiment may include the steps of: preparing a first solution mixed with beta-cyclodextrin and water (S10); preparing a second solution mixed with menthol and ethanol (S20); mixing the first solution and the second solution to prepare a menthol freeze-drying composition (S30); freezing the menthol freeze-drying composition (S40); and drying the frozen menthol freeze-drying composition (S50).
[0026] Specifically, the method may comprise: a) a step of preparing a first solution by mixing beta-cyclodextrin and water; b) a step of preparing a second solution by mixing menthol and ethanol; c) a step of preparing a menthol freeze-drying composition by mixing the first solution and the second solution; d) a step of freezing the menthol freeze-drying composition at -40°C to -50°C using a deep freezer; and e) a step of drying the composition frozen in step d) at -40°C to -50°C.
[0027] According to the embodiments, a method for manufacturing freeze-dried menthol powder can be provided, which allows highly volatile menthol to be manufactured in powder form while maintaining a constant yield.
[0028] Menthol is highly volatile, so a significant amount of flavor evaporates upon drying, making it difficult to manufacture in powder form. However, by using the method for manufacturing freeze-dried menthol powder according to the example, freeze-dried menthol powder with a relatively high powder yield and menthol yield can be produced. In addition, the freeze-dried menthol powder produced by the above method has the advantage of being easy to store.
[0029] According to the embodiment, step a) can be performed by heating water. Beta-cyclodextrin may be added to the heated water, or the mixed solution may be heated after adding beta-cyclodextrin to the water. The first solution mixed with beta-cyclodextrin and water may be about 40°C to about 80°C. Beta-cyclodextrin may be added to the water in powder form. Step a) may include a process of mixing beta-cyclodextrin and water and then homogenizing through a homogenizer.
[0030] According to the example, step b) can be performed to increase the solubility of menthol. Since menthol is almost insoluble in water, a step of dissolving it in ethanol first can be performed, followed by step c) of mixing it with the first solution prepared in step a). If ethanol is not included when preparing the composition for freeze-drying menthol, menthol is not dissolved in the composition, and even if the composition for freeze-drying menthol is freeze-dried, the menthol yield of the produced powder may be significantly lower. Additionally, if a step of sufficiently dissolving menthol in ethanol, as in step b), is not performed separately from step a), the menthol yield of the powder produced by freeze-drying may decrease.
[0031] According to the example, step d) can improve the menthol yield by preventing layer separation of the menthol freeze-drying composition prepared in step c) and minimizing the loss of menthol in the solution by freezing it in a deep freezer at -40°C to -50°C. According to the example, the freezing in step d) may be performed for about 24 hours, but is not limited thereto.
[0032] According to the example, step e) may produce menthol freeze-dried powder by drying the menthol freeze-drying composition frozen through step d). Step e) may be performed at -40°C to -50°C for 48 to 72 hours. Additionally, step e) may be performed at a vacuum of 20 mmAq or less. Alternatively, it may be performed at a vacuum of 10 mmAq or less. However, the drying time and vacuum level, etc., may vary depending on the drying target, drying environment, etc.
[0033] FIG. 2 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to another embodiment.
[0034] According to an example, the method for manufacturing menthol freeze-dried powder may further include a step of ultrasonically treating the menthol freeze-drying composition prepared through step c) with an ultrasonic homogenizer between step c) and step d). That is, in FIG. 1, between steps S30 and S40, a step (S35) of ultrasonically treating the menthol freeze-drying composition may further include.
[0035] Referring to FIG. 2, a method for manufacturing menthol freeze-dried powder according to an embodiment may include the steps of: preparing a first solution mixed with beta-cyclodextrin and water (S10); preparing a second solution mixed with menthol and ethanol (S20); mixing the first solution and the second solution to prepare a menthol freeze-drying composition (S30); ultrasonically treating the menthol freeze-drying composition (S35); freezing the ultrasonically treated menthol freeze-drying composition (S40); and drying the frozen menthol freeze-drying composition (S50).
[0036] When a menthol freeze-drying composition is subjected to ultrasonic treatment and freeze-dried, the yield of the freeze-dried powder can be increased, and the particle size of the entire powder is reduced, making it suitable for use as an inhalation powder.
[0037] According to the example, the beta-cyclodextrin included in the above-described menthol freeze-drying composition may be in a hydrated form. When the hydrated beta-cyclodextrin is included in the menthol freeze-drying composition and freeze-dried, a menthol freeze-dried powder having a high menthol yield can be produced.
[0038] According to the examples, menthol and beta-cyclodextrin may be included in a weight ratio of 1:3 to 1:10. If beta-cyclodextrin is used in an amount less than the range, it may not sufficiently include menthol, and if beta-cyclodextrin is used in an amount greater than the range, the inclusion efficiency may decrease and the solubility of the menthol freeze-drying composition may decrease.
[0039] According to the example, the menthol freeze-drying composition may comprise, based on the total weight of the menthol freeze-drying composition, 1% to 5% by weight of menthol, 3% to 50% by weight of beta-cyclodextrin, 1% to 10% by weight of ethanol, and the remainder being water.
[0040] If the beta-cyclodextrin is contained in an amount less than the above range, the freeze-dried powder may not be properly formed and the menthol yield may decrease, and if the beta-cyclodextrin is contained in an amount more than the above range, the freeze-drying time may increase and the overall process efficiency may decrease.
[0041] If the ethanol content is less than the above range, the menthol may not dissolve properly, and if the ethanol content is more than the above range, freeze-drying may not proceed smoothly and may cause a malfunction of the freeze-drying device.
[0042] FIG. 3 is a flowchart illustrating a method for manufacturing menthol freeze-dried powder according to another embodiment.
[0043] According to an example, the method for manufacturing menthol freeze-dried powder may be such that step c) described above is a step of mixing the first solution of step a) and the second solution of step b) and then adding a cryoprotectant to prepare a menthol freeze-drying composition. That is, in step c), the menthol freeze-drying composition may be one in which a cryoprotectant is added after mixing the first solution and the second solution. When the menthol freeze-drying composition further includes a cryoprotectant, menthol freeze-dried powder having a relatively high menthol yield can be manufactured.
[0044] That is, in FIG. 1, step S30 may be a step of mixing the first solution and the second solution, and then adding a cryoprotectant to prepare a composition for freeze-drying menthol.
[0045] Referring to FIG. 3, a method for manufacturing menthol freeze-dried powder according to an embodiment may include the steps of: preparing a first solution mixed with beta-cyclodextrin and water (S10); preparing a second solution mixed with menthol and ethanol (S20); mixing the first solution and the second solution, and then adding a cryoprotectant to prepare a menthol freeze-drying composition (S30); freezing the ultrasonically treated menthol freeze-drying composition (S40); and drying the frozen menthol freeze-drying composition (S50).
[0046] According to the examples, the cryoprotectant may be one or more selected from the group consisting of trehalose, mannitol, and xylitol. By including the cryoprotectant, the freeze-drying composition according to the examples can increase the powder yield and menthol yield.
[0047] The method for manufacturing menthol freeze-dried powder according to the example may further include the step of using trehalose as a cryoprotective agent and ultrasonically treating the menthol freeze-drying composition with an ultrasonic homogenizer between step c) and step d). Through this manufacturing method, the menthol yield in the menthol freeze-dried powder can be improved.
[0048] According to the example, the menthol freeze-drying composition may comprise, based on the total weight of the menthol freeze-drying composition, 1% to 5% by weight of menthol, 3% to 50% by weight of beta-cyclodextrin, 0.1% to 2% by weight of cryoprotectant, 1% to 10% by weight of ethanol, and the remainder being water.
[0049] If the cryoprotectant is included in a smaller amount than the above range, the effect of increasing powder yield and menthol yield is negligible, and if the cryoprotectant is included in a larger amount than the above range, the freeze-drying time increases and the stability of the freeze-drying formulation may decrease.
[0050] According to the embodiments, a freeze-dried menthol powder may be provided, comprising a menthol freeze-drying composition according to the embodiments described above. The menthol freeze-dried powder according to the embodiments may have the advantage of being easy to store.
[0051] In addition, through the embodiments, a stick for a dry powder inhaler (DPI) comprising the menthol freeze-dried powder described above may be provided. The dry powder inhaler is designed to deliver nicotine powder (1% or less by weight) directly to the user's airway by inhaling the dry powder, and may be manufactured in the form of a stick similar to a smoking product.
[0052] The menthol freeze-dried powder according to the embodiment can be easily applied to a stick for a dry powder inhaler. A stick for a dry powder inhaler containing the menthol freeze-dried powder according to the embodiment can provide a menthol flavor when inhaled by a user.
[0053] When applying menthol in powder form to a stick for a dry powder inhaler, it can be applied more easily than liquid flavoring material. In addition, when liquid flavoring material is included in a capsule, etc., it is necessary to apply oil-resistant wrapping paper to reduce the wrapping paper from wetting due to the flavoring material; however, according to the embodiment, the need to apply oil-resistant wrapping paper is reduced, thereby simplifying the manufacturing process and reducing manufacturing costs.
[0054] The dry powder inhaler stick according to the embodiment contains nicotine powder, and the user can inhale the dry powder by inhalation, similar to a general smoking product. The dry powder inhaler stick according to the embodiment can be manufactured so that the dry powder is easily inhaled with an inhalation pressure similar to that when using a general smoking product.
[0055] In one embodiment, a stick for a dry powder inhaler may include a shear section, a medium section, and a filter section based on the longitudinal direction. The "longitudinal direction" of the stick may refer to the direction in which the length of the stick extends. Alternatively, it may refer to the direction of the main airflow through which external air enters the user's mouth when the user inhales the stick.
[0056] According to one embodiment, the medium portion of a dry powder inhaler stick contains dry nicotine powder. By the user contacting the end portion of a filter portion located downstream of the medium portion and inhaling, the powder contained in the medium portion of the dry powder inhaler stick can be inhaled into the user's mouth.
[0057] Specifically, when a user inhales the dry powder inhaler stick according to the embodiment, external air introduced through the front section reaches the medium section, and the introduced external air passes through the filter section together with the nicotine powder and can be delivered to the user's oral cavity. However, the structure of the dry powder inhaler stick is not limited to that described above.
[0058] According to one embodiment, the menthol freeze-dried powder produced by the above-described manufacturing method may be included in one or more of the shear portion, medium portion, and filter portion of the dry powder inhaler stick.
[0059] According to another embodiment, the menthol freeze-dried powder produced by the manufacturing method described above may be contained in a wrapper surrounding one or more of the shear portion, medium portion, and filter portion of the stick for the dry powder inhaler. The menthol freeze-dried powder may be applied to the inner or outer surface of the wrapper.
[0060] All embodiments described above in this specification may be combined with each other.
[0061] The invention will be explained in more detail below through examples and experimental examples. These examples are merely illustrative, and it will be obvious to those skilled in the art that the invention is not to be interpreted as being limited by these examples.
[0062]
[0063] <Example>
[0064] 1. Experimental Example 1: Preparation of Composition for Freeze-Drying Menthol and Yield Comparison Experiment
[0065] The menthol freeze-drying compositions of Examples 1 to 4 were prepared, and the freeze-drying process was carried out. A freeze-drying composition was prepared by mixing menthol (L-Menthol, DAEHUNG, Seoul, Korea) and β-Cyclodextrin (hydrate, 99.0%, SAMCHUN, Gyeonggi-do, Korea), and then the freeze-drying process was applied.
[0066] The composition of each composition is as shown in Table 1 below.
[0067] Ingredients (Weight%) Example 1 Example 2 Example 3 Example 4 β-Cyclodextrin 15 14 14 14 Menthol 3 3 3 Cryoprotectant 1.5 (Trehalose) 1.5 (Mannitol) 1.5 (Xylitol) Ethanol 5 4.5 4.5 4.5 Distilled Water 7 7 7 7 7 7 7 Total 1 0 1 0 1 0 1 0 1 0
[0068]
[0069] For Example 1, β-Cyclodextrin was added to distilled water at 50°C and homogenized at 400 rpm for 1 hour. Menthol was dissolved in an ethanol solution and then mixed with the β-Cyclodextrin solution. It was confirmed that if the process of sufficiently dissolving menthol in an ethanol solution was not performed separately, the yield of menthol decreased, and the cooling sensation was significantly lowered even when prepared as a freeze-dried powder.
[0070] Subsequently, the mixed composition is deep-frozen (FDE60086FD, FORMA TM The sample was frozen at -45°C for 24 hours using a Thermo Fisher Scientific (HyperCOOL 3110, Labogene) and then dried at -45°C for 72 hours. Freeze-drying was performed using a cold trap (HyperCOOL 3110, Labogene) with a 4 L capacity chamber and internal dimensions of φ30 × 40 cm, and a rotary vane pump (W2V20, WSA, Gyeonggi-do, Korea) was used as the vacuum pump. During the freeze-drying process, changes in sample weight were recorded in real-time using a digital balance installed in the vacuum chamber, spread out, and utilized to calculate the drying rate.
[0071] For Examples 2 to 4, β-Cyclodextrin was added to distilled water at 50°C and homogenized at 400 rpm for 1 hour. Menthol was dissolved in an ethanol solution and then mixed with the β-Cyclodextrin solution. Trehalose (Example 2), Mannitol (Example 3), and Xylitol (Example 4) were added to the mixed solution as cryoprotectants, respectively. Subsequently, the freezing and drying processes were carried out as in Example 1.
[0072] After freeze-drying using the compositions of Examples 1 to 4 above, the powder yield and menthol yield were measured. The powder and menthol yields were calculated as the ratio of the sample solid after freeze-drying to the sample solid after initial input, as shown in Equation 1 below.
[0073] [Mathematical Formula 1]
[0074]
[0075] (S r : Final solid weight S after freeze-drying t : Initial input solid weight)
[0076] Using the above mathematical formula 1, the powder yield was calculated by measuring the weight of the initial input solids excluding the solvent and the weight of the powder after freeze-drying. In addition, the menthol yield was calculated by measuring the weight of the initial input menthol and the weight of menthol in the powder after freeze-drying. The weight of menthol in the powder after freeze-drying was quantitatively analyzed by gas chromatography (Agilent GC6890, Agilent Technologies) after dissolving the powder in methanol. The menthol content was analyzed after adding the freeze-dried menthol powder to methanol and shaking it at 200 rpm with a shaker for 1 hour.
[0077] The measurement results are shown in Table 2 below.
[0078] Yield (%) Example 1 Example 2 Example 3 Example 4 Powder yield 84.33 89.30 90.92 86.83 Menthol yield 62.40 70.60 77.70 68.40
[0079]
[0080] As a result of the experiment, Examples 1 to 4 all showed relatively high powder yield and menthol yield, and among them, Example 3, which used Mannitol as a cryoprotectant, was found to have the highest powder yield at 90.92% and menthol yield at 77.70%.
[0081] Meanwhile, the composition of Comparative Example 1 containing Maltodextrin instead of β-Cyclodextrin was prepared according to the composition of Table 3 below, and then the freeze-drying process as in Example 1 was applied.
[0082] Comparative Example of Ingredients (Weight%) 1 Maltodextrin 15 Menthol 3 Ethanol 5 Distilled Water 77 Total 100
[0083]
[0084] As a result of freeze-drying, in the case of Comparative Example 1, clumping occurred because the drying of the powder was incomplete. Accordingly, it was confirmed that the composition of Comparative Example 1 is unsuitable for manufacturing freeze-dried menthol powder for inhalation.
[0085]
[0086] 2. Experimental Example 2: Experiment on Yield Change According to the Presence or Absence of Ultrasonic Treatment
[0087] Using the compositions of Examples 1 to 4 obtained in Experimental Example 1 above, ultrasonic treatment was performed prior to freeze-drying, and then the powder yield and menthol yield were measured. The compositions of Examples 1 to 4 were ultrasonically treated at 200 W for 5 minutes using an ultrasonic homogenizer (SONOPULS HD 4200, BANDELIN, Berlin, Germany), and then the freeze-drying process was applied as in Experimental Example 1.
[0088] The powder and menthol yields were calculated as the ratio of the sample solids after freeze-drying to the sample solids after initial input using Equation 1, as in Experimental Example 1 described above. The measurement results are shown in Table 4 below.
[0089] Yield (%) Example 1 Example 2 Example 3 Example 4 Powder yield Ultrasonic untreated 84.33 89.30 90.9 286.83 Ultrasonic treated 85.75 88.11 96.70 85.32 Menthol yield Ultrasonic untreated 62.40 70.60 77.70 68.40 Ultrasonic treated 62.30 73.70 76.90 62.60
[0090]
[0091] As a result of the experiment, it was confirmed that when the compositions of Example 1 and Example 3 were treated with ultrasound and freeze-dried, the menthol yield was similar, but the yield of the total freeze-dried powder increased slightly. In addition, it was confirmed that when the composition of Example 2 was treated with ultrasound and freeze-dried, the menthol yield increased by approximately 3.1%.
[0092]
[0093] 3. Experimental Example 3: Particle Size Analysis According to the Presence or Absence of Ultrasonic Treatment
[0094] The composition of Example 5 was prepared in the same manner as in Experimental Example 1 above. The composition of Example 5 is as shown in Table 5 below.
[0095] Ingredients (Weight%) Example 5 β-Cyclodextrin 1 4 Menthol 3 Mannitol 2 Ethanol 5 Distilled Water 7 6 Total 100
[0096]
[0097] The composition of Example 5 was ultrasonically treated and then freeze-dried, and the particle size of the freeze-dried menthol powder was analyzed. The particle size of the powder was measured in μm units using a Laser Diffraction Particle Size Analyzer (LS 13320 XR, Beckman Coulter, CA, USA). The measurement results are shown in Table 6 below.
[0098] Particle Size (㎛) Ultrasonic Untreated Ultrasonic Treated Minimum 0.37±0.01 a 0.37±0.02 a Median 15.13±0.13 a 12.65±0.35 b Max256.41±0.42 a 133.65±0.18 b Mean21.91±0.64 a 16.25±0.13 b
[0099]
[0100] As a result of the experiment, there was no significant difference in the minimum particle size depending on whether ultrasonic treatment was performed or not. However, when ultrasonic treatment was performed compared to when ultrasonic treatment was not performed, the median, maximum, and mean particle sizes were significantly reduced. Therefore, it was found that when a menthol freeze-drying composition is subjected to ultrasonic treatment followed by freeze-drying, the powder has a smaller particle size and is therefore more suitable for inhalation.
[0101] The description of the embodiments described above is merely illustrative, and those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible therefrom. Accordingly, the true scope of protection of the invention should be determined by the appended claims, and all variations within the scope equivalent to that described in the claims should be interpreted as being included within the scope of protection determined by the claims.
Claims
1. A method for manufacturing freeze-dried menthol powder, a) a step of preparing a first solution by mixing beta-cyclodextrin (β-Cyclodextrin) and water; b) a step of preparing a second solution by mixing menthol and ethanol; c) a step of preparing a menthol freeze-drying composition by mixing the first solution and the second solution; d) freezing the menthol freeze-drying composition at -40 ℃ to -50 ℃ using a deep freezer; and e) a step of drying the composition frozen in step d) at -40 ℃ to -50 ℃; comprising a method for manufacturing menthol freeze-dried powder.
2. In Paragraph 1, A method for manufacturing menthol freeze-dried powder, further comprising the step of ultrasonically treating the menthol freeze-drying composition with an ultrasonic homogenizer between the above step c) and the above step d).
3. In Paragraph 1, A method for manufacturing freeze-dried menthol powder, wherein the menthol and the beta-cyclodextrin are included in a weight ratio of 1:3 to 1:
10.
4. In Paragraph 1, Based on the total weight of the above menthol freeze-drying composition, A method for preparing menthol freeze-dried powder, wherein the above menthol freeze-drying composition comprises 1% to 5% by weight of the menthol, 3% to 50% by weight of the beta-cyclodextrin, 1% to 10% by weight of ethanol, and the remainder being water.
5. In Paragraph 1, A method for preparing menthol freeze-dried powder in which the above beta-cyclodextrin is in a hydrated form.
6. In Paragraph 1, A method for manufacturing menthol freeze-dried powder, wherein in step c) above, the menthol freeze-drying composition is prepared by mixing the first solution and the second solution, and then adding a cryoprotective agent.
7. In Paragraph 6, A method for manufacturing menthol freeze-dried powder, wherein the cryoprotectant is one or more selected from the group consisting of trehalose, mannitol, and xylitol.
8. In Paragraph 6, A method for manufacturing menthol freeze-dried powder, comprising, between step c) and step d), a step of ultrasonically treating the menthol freeze-drying composition with an ultrasonic homogenizer, wherein the cryoprotectant is trehalose.
9. In Paragraph 6, Based on the total weight of the above menthol freeze-drying composition, A method for manufacturing menthol freeze-dried powder, comprising 0.1% to 2% by weight of the above cryoprotectant.
10. Menthol freeze-dried powder manufactured through the method of any one of claims 1 to 9.
11. A stick for a dry powder inhaler comprising the menthol freeze-dried powder of claim 10.
